Exciting Developments at Lexeo Therapeutics
Lexeo Therapeutics, Inc. (NASDAQ: LXEO), a prominent name in genetic medicine, is preparing for an exciting series of presentations at key investor conferences. This forward-thinking company aims to transform treatments for genetically defined cardiovascular diseases and Alzheimer’s disease associated with the APOE4 gene variant.
Upcoming Investor Conferences
In line with its dedication to transparency and engaging with investors, Lexeo's management team will participate in several events where they will share valuable insights and updates on their groundbreaking initiatives.
H.C. Wainwright 26th Annual Global Investment Conference
This important event is scheduled for Monday, September 9, 2024, at 10:00 AM ET. It will serve as a platform for Lexeo to connect with investors and discuss their strategic plans moving forward.
Baird 2024 Global Healthcare Conference
On Tuesday, September 10, 2024, at 1:25 PM ET, Lexeo will present at the Baird conference, continuing to showcase their advancements and vision for the future of healthcare.
Cantor 2024 Global Healthcare Conference
Set for Wednesday, September 18, 2024, at 11:30 AM ET, this conference will further highlight Lexeo’s commitment to developing innovative therapies.
Chardan’s 8th Annual Genetic Medicines Conference
On Tuesday, October 1, 2024, at 2:30 PM ET, Lexeo will conclude this series of presentations at Chardan’s conference, underscoring the vital role of genetic medicine in enhancing patient care.
Webcast Accessibility
For those who cannot attend in person, Lexeo will offer live webcasts of these events. Recordings will also be available for later viewing on their website, ensuring that all stakeholders can stay updated on the latest developments.
About Lexeo Therapeutics
Headquartered in New York City, Lexeo Therapeutics is at the cutting edge of genetic medicine. The company is dedicated to employing innovative scientific methods to significantly improve treatments for diseases that are genetically influenced. Their commitment to advancing therapies is evident in their strategies, which combine early research findings with functional outcomes.
Lexeo is particularly focused on tackling the challenges presented by cardiovascular diseases and Alzheimer’s linked to the APOE4 gene variant. Through their dedicated efforts, Lexeo is poised to make substantial progress in this crucial area of healthcare.
Contact Information
Media Inquiries:
For any media-related questions, please contact us via email at media@lexeotx.com.
Investor Relations:
For inquiries related to investors, please reach out to Stephen Jasper at (858) 525-2047 or via email at stephen@gilmartinir.com.
Frequently Asked Questions
What is the focus of Lexeo Therapeutics?
Lexeo Therapeutics is dedicated to developing innovative treatments for genetically defined cardiovascular diseases and Alzheimer’s disease associated with the APOE4 gene variant.
When are the upcoming investor conferences?
The conferences are scheduled to take place from September 9 to October 1, 2024.
What is a webcast, and how can I access it?
A webcast is a live stream of the conferences, which will also be available for later viewing on Lexeo's official website.
Who should I contact for investor relations?
For investor inquiries, Stephen Jasper is the designated contact, and he can be reached by phone or email.
How does Lexeo approach disease treatment?
Lexeo utilizes a stepwise development strategy, leveraging early proof-of-concept data to enhance their treatment pipeline.